Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device.

Krieter PA, Chiang CN, Gyaw S, McCann DJ.

J Clin Pharmacol. 2019 Aug;59(8):1078-1084. doi: 10.1002/jcph.1401. Epub 2019 Mar 12.

PMID:
30861160
2.

Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) rats.

Yang AR, Yi HS, Warnock KT, Mamczarz J, June HL Jr, Mallick N, Krieter PA, Tonelli L, Skolnick P, Basile AS, June HL Sr.

Alcohol Clin Exp Res. 2012 May;36(5):863-73. doi: 10.1111/j.1530-0277.2011.01671.x. Epub 2011 Dec 7.

3.

The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity.

Tizzano JP, Stribling DS, Perez-Tilve D, Strack A, Frassetto A, Chen RZ, Fong TM, Shearman L, Krieter PA, Tschöp MH, Skolnick P, Basile AS.

J Pharmacol Exp Ther. 2008 Mar;324(3):1111-26. Epub 2007 Dec 18.

PMID:
18089843
4.

Pharmacokinetics, disposition, and metabolism of bicifadine in humans.

Krieter PA, Gohdes M, Musick TJ, Duncanson FP, Bridson WE.

Drug Metab Dispos. 2008 Feb;36(2):252-9. Epub 2007 Nov 8.

PMID:
17991768
5.

Pharmacokinetics, disposition, and metabolism of bicifadine in the mouse, rat, and monkey.

Musick TJ, Gohdes M, Duffy A, Erickson DA, Krieter PA.

Drug Metab Dispos. 2008 Feb;36(2):241-51. Epub 2007 Nov 8.

PMID:
17991767
6.

In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human.

Erickson DA, Hollfelder S, Tenge J, Gohdes M, Burkhardt JJ, Krieter PA.

Drug Metab Dispos. 2007 Dec;35(12):2232-41. Epub 2007 Sep 19.

PMID:
17881661
7.

Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain.

Basile AS, Janowsky A, Golembiowska K, Kowalska M, Tam E, Benveniste M, Popik P, Nikiforuk A, Krawczyk M, Nowak G, Krieter PA, Lippa AS, Skolnick P, Koustova E.

J Pharmacol Exp Ther. 2007 Jun;321(3):1208-25. Epub 2007 Feb 26.

PMID:
17325229
8.

Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys.

Vincent SH, Painter SK, Krieter PA, Colletti AE, Lyszack E, Rosegay A, Dean D, Luffer-Atlas D, Miller RR, Cioffe C, Chiu SH.

Drug Metab Dispos. 1996 Dec;24(12):1369-77.

PMID:
8971144
9.

Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine.

Krieter PA, Colletti AE, Miller RR, Stearns RA.

J Pharmacol Exp Ther. 1995 May;273(2):816-22.

PMID:
7752085
10.

Disposition and metabolism of the hypoglycemic agent pioglitazone in rats.

Krieter PA, Colletti AE, Doss GA, Miller RR.

Drug Metab Dispos. 1994 Jul-Aug;22(4):625-30.

PMID:
7956739
11.

Disposition of the angiotensin II receptor antagonist L-158,809 in rats and rhesus monkeys.

Colletti AE, Krieter PA.

Drug Metab Dispos. 1994 Mar-Apr;22(2):183-8.

PMID:
8013272
12.

Highly potent, orally active diester macrocyclic human renin inhibitors.

Weber AE, Steiner MG, Krieter PA, Colletti AE, Tata JR, Halgren TA, Ball RG, Doyle JJ, Schorn TW, Stearns RA, et al.

J Med Chem. 1992 Oct 16;35(21):3755-73.

PMID:
1433190
13.

In vivo metabolism of atrial natriuretic peptide: identification of plasma metabolites and enzymes responsible for their generation.

Krieter PA, Olins GM, Verrett SP, Durley RC.

J Pharmacol Exp Ther. 1989 May;249(2):411-7.

PMID:
2524586
14.

Specific inhibitors of endopeptidase 24.11 inhibit the metabolism of atrial natriuretic peptides in vitro and in vivo.

Olins GM, Krieter PA, Trapani AJ, Spear KL, Bovy PR.

Mol Cell Endocrinol. 1989 Feb;61(2):201-8.

PMID:
2521834
15.

Metabolism of atrial natriuretic peptide. Extraction by organs in the rat.

Krieter PA, Trapani AJ.

Drug Metab Dispos. 1989 Jan-Feb;17(1):14-9.

PMID:
2566463
16.

Immunoquantitation of cytochrome b5 and methylcholanthrene-induced cytochromes P-450.

Shires TK, Krieter PA, Shawver LK, Seidel SL.

Fed Proc. 1987 Jun;46(8):2567-74. Review.

PMID:
2439385
17.
18.

Studies on the biliary efflux of GSH from rat liver due to the metabolism of aminopyrine.

Krieter PA, Ziegler DM, Hill KE, Burk RF.

Biochem Pharmacol. 1985 Apr 1;34(7):955-60.

PMID:
3985999
19.
21.

Cytochrome P-450 and halothane metabolism. Decrease in rat liver microsomal P-450 in vitro.

Krieter PA, van Dyke RA.

Chem Biol Interact. 1983 Jun;44(3):219-35.

PMID:
6872091
22.

Distributions of monooxygenase components and epoxide hydratase within the livers of untreated male rats.

Redick JA, Kawabata TT, Guengerich FP, Krieter PA, Shires TK, Baron J.

Life Sci. 1980 Dec 22-29;27(25-26):2465-70. No abstract available.

PMID:
6783796
23.

Cell-free translation of apocytochrome b5 messenger RNA and analysis of the peptide product.

Krieter PA, Shires TK.

Biochem Biophys Res Commun. 1980 May 30;94(2):606-11. No abstract available.

PMID:
7396923

Supplemental Content

Loading ...
Support Center